Table 1

Comparison of demographic, clinical, and laboratory results in PMR patients with or without response to 12.5 mg daily of prednisone

FEATURE

RESPONDERS

NON RESPONDERS

p


Number

47 (78.3%)

13 (21.7%)


Gender (women/men)

31/16

4/9

0.05


Age (years)

71.3 ± 7.1

71.5 ± 7.9

0.95


Weight (kg)

67.4 ± 11.4

78.5 ± 13.9

0.004


Disease duration (days)

90 (12-720)

86 (24-210)

0.32


Morning stiffness (minutes)

100.7 ± 85.9

89.0 ± 52.2

0.69


Fatigue

26 (55.3%)

10 (76.9%)

0.28


Fever

10 (21.3%)

3 (30%)

0.81


Weight loss

16 (34%)

2 (15.4%)

0.34


Peripheral arthritis

13 (27.7%)

4 (30.8%)

0.89


Carpal tunnel syndrome

16 (34.0%)

2 (15.4%)

0.34


RS3PE

8 (17.0%)

2 (15.4%)

0.78


Tenosynovitis

4 (8.5%)

1 (7.7%)

0.64


ESR (mm/h)

63.8 ± 25.8

62.5 ± 22.4

0.88


CRP (mg/L)

30 (1.5-180)

30 (2.5-247)

0.96


Cimmino et al. BMC Musculoskeletal Disorders 2011 12:94   doi:10.1186/1471-2474-12-94

Open Data